What is the appropriate dosing of Eliquis (apixaban) for a patient in their late 80s with chronic kidney disease stage 3 being treated for an acute deep‑vein thrombosis?

Apixaban Dosing for Acute DVT in a Patient ≥80 Years with CKD Stage 3

For acute DVT treatment in a patient in their late 80s with CKD stage 3, use the standard VTE dosing regimen: apixaban 10 mg orally twice daily for 7 days, then 5 mg orally twice daily for at least 3–6 months. 1 Age and CKD stage 3 alone do not trigger dose reduction for VTE treatment—the dose-reduction criteria apply only to atrial fibrillation, not DVT. 2, 1

Critical Distinction: VTE vs. Atrial Fibrillation Dosing

• Do not apply the atrial fibrillation dose-reduction criteria (age ≥80 years + weight ≤60 kg or serum creatinine ≥1.5 mg/dL) to VTE treatment. 2 These criteria are indication-specific and were designed exclusively for stroke prevention in AF, not for acute thrombosis. 3

• The standard VTE maintenance dose is 5 mg twice daily, which must not be confused with the 2.5 mg twice-daily dose used in selected AF patients. 2, 1

Initial Treatment Phase (Days 1–7)

• Start apixaban 10 mg orally twice daily for exactly 7 days without any preceding heparin or enoxaparin. 1 This loading regimen was validated in the AMPLIFY trial and eliminates the need for parenteral bridging. 2

• No dose adjustment is required for CKD stage 3 (CrCl 30–59 mL/min) during the acute treatment phase. 4, 5

Maintenance Treatment Phase (Day 8 Onward)

• Continue apixaban 5 mg orally twice daily starting on day 8. 1

• Treat for a minimum of 3 months if the DVT was provoked (e.g., surgery, trauma, immobilization) or 3–6 months if unprovoked. 6, 2

• CKD stage 3 does not require dose reduction during maintenance therapy; the 5 mg twice-daily dose is appropriate across CrCl 30–59 mL/min. 4, 5

Extended Secondary Prevention (Beyond 6 Months)

• If the patient has unprovoked DVT or persistent risk factors and requires anticoagulation beyond 6 months, reduce to apixaban 2.5 mg orally twice daily after completing at least 6 months of the standard 5 mg twice-daily regimen. 6, 2, 1

• The reduced-dose extended prophylaxis (2.5 mg BID) maintains VTE prevention while lowering major bleeding risk compared to continued full-dose therapy. 6, 2

Renal Function Monitoring in CKD Stage 3

• CKD stage 3 (CrCl 30–59 mL/min) is considered moderate renal impairment and does not require dose adjustment for VTE treatment with apixaban. 4, 5

• Reassess renal function at least annually and when clinically indicated, as progressive CKD may eventually require consideration of alternative agents if CrCl falls below 25–30 mL/min. 5

• Apixaban should be avoided in severe renal impairment (CrCl <15 mL/min or dialysis-dependent) for VTE treatment, as patients with CrCl <25 mL/min were excluded from pivotal trials. 2 However, emerging observational data suggest that reduced-dose apixaban (2.5 mg BID) may be safer than standard dosing in severe CKD/ESRD for VTE treatment, with lower bleeding rates and similar VTE recurrence. 7, 8

Common Pitfalls to Avoid

• Do not initiate therapy at 5 mg twice daily; the 7-day loading phase with 10 mg twice daily is essential for acute VTE treatment. 2, 1

• Do not use the 2.5 mg twice-daily dose during the initial 6 months unless the patient is in the extended secondary prevention phase after completing standard therapy. 6, 2

• Do not bridge with heparin or enoxaparin; apixaban can be started immediately as monotherapy for acute DVT. 2, 1

• Do not confuse the VTE maintenance dose (5 mg BID) with the AF dose, which may be 2.5 mg BID in selected patients meeting two of three dose-reduction criteria. 2, 1

Drug Interactions Requiring Dose Adjustment

• Reduce the apixaban dose by 50% when co-administered with combined P-glycoprotein and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir). 1

• For patients already on the reduced 2.5 mg twice-daily regimen, avoid co-administration with these strong dual inhibitors. 1

Clinical Evidence Supporting Standard Dosing in This Population

• The AMPLIFY trial demonstrated that apixaban 10 mg BID × 7 days → 5 mg BID was non-inferior to enoxaparin/warfarin for preventing recurrent VTE (2.3% vs. 2.7%) and achieved a 69% relative risk reduction in major bleeding (0.6% vs. 1.8%, P <0.001). 2

• Real-world data from 29,790 VTE patients with CKD showed that apixaban was associated with significantly lower risk of recurrent VTE (HR 0.78) and major bleeding (HR 0.76) compared to warfarin, with no significant interaction by CKD stage. 9 This supports the use of standard VTE dosing even in moderate renal impairment.

• A 2024 meta-analysis confirmed that DOACs, including apixaban, reduced major bleeding compared to vitamin K antagonists in CKD stage 4 and stage 5/dialysis patients (OR 0.73 and 0.70, respectively). 10